User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.

Primary tabs

McCormack, Ann Dekkers, Olaf M Petersenn, Stephan Popovic, Vera Trouillas, Jacqueline ESE survey collaborators

To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment. Electronic survey to ESE members Dec 2015-Nov 2016. Reports on 166 patients (40 PC, 125 APT, 1 unclassified) were obtained. Median age at diagnosis was 43 (range 4-79) years. 69% of the tumours were clinically functioning, and the most frequent immunohistochemical subtype were corticotroph tumours (45%). Ki-67 index did not distinguish APT from PC, median 7% and 10% respectively. TMZ was first-line chemotherapy in 157 patients. At the end of the treatment (median 9 cycles), radiological evaluation showed complete response (CR) in 6%, partial response (PR) in 31%, stable disease (SD) in 33% and progressive disease in 30%. Response was more frequent in patients receiving concomitant radiotherapy and TMZ. CR was seen only in patients with low MGMT expression. Clinically functioning tumours were more likely to respond than non-functioning tumours, independent of MGMT status. Of patients with CR, PR and SD, 25, 40 and 48% respectively progressed after a median of 12-month follow-up. Other oncological drugs given as primary treatment and to TMZ failures resulted in PR in 20%. This survey confirms that TMZ is established as first-line chemotherapeutic treatment of APT/PC. Clinically functioning tumours, low MGMT and concurrent radiotherapy were associated with a better response. The limited long-term effect of TMZ and the poor efficacy of other drugs highlight the need to identify additional effective therapies.

Document type Article de périodique (Journal article)
Publication date 2018
Language Anglais
Journal information "European journal of endocrinology" - Vol. 178, no.3, p. 265-276 (2018)
e-issn 1479-683X
Publication status Publié
Affiliation UCL - (SLuc) Service de soins intensifs
Links
  1. Heaney Anthony P., Pituitary Carcinoma: Difficult Diagnosis and Treatment, 10.1210/jc.2011-2031
  2. Pernicone Peter J., Scheithauer Bernd W., Sebo Thomas J., Kovacs Kalman T., Horvath Eva, Young William F., Lloyd Ricardo V., Davis Dudley H., Guthrie Barton L., Schoene William C., Pituitary carcinoma : A clinicopathologic study of 15 cases, 10.1002/(sici)1097-0142(19970215)79:4<804::aid-cncr18>3.0.co;2-3
  3. Ragel Brian T., Couldwell William T., Pituitary carcinoma: a review of the literature, 10.3171/foc.2004.16.4.8
  4. Kaltsas G. A., The Role of Cytotoxic Chemotherapy in the Management of Aggressive and Malignant Pituitary Tumors, 10.1210/jc.83.12.4233
  5. Losa Marco, Bogazzi Fausto, Cannavo Salvo, Ceccato Filippo, Curtò Lorenzo, De Marinis Laura, Iacovazzo Donato, Lombardi Giuseppe, Mantovani Giovanna, Mazza Elena, Minniti Giuseppe, Nizzoli Maurizio, Reni Michele, Scaroni Carla, Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas, 10.1007/s11060-015-1991-y
  6. Lasolle Hélène, Cortet Christine, Castinetti Fréderic, Cloix Lucie, Caron Philippe, Delemer Brigitte, Desailloud Rachel, Jublanc Christel, Lebrun-Frenay Christine, Sadoul Jean-Louis, Taillandier Luc, Batisse-Lignier Marie, Bonnet Fabrice, Bourcigaux Nathalie, Bresson Damien, Chabre Olivier, Chanson Philippe, Garcia Cyril, Haissaguerre Magalie, Reznik Yves, Borot Sophie, Villa Chiara, Vasiljevic Alexandre, Gaillard Stephan, Jouanneau Emmanuel, Assié Guillaume, Raverot Gérald, Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas, 10.1530/eje-16-0979
  7. Stupp Roger, Mason Warren P., van den Bent Martin J., Weller Michael, Fisher Barbara, Taphoorn Martin J.B., Belanger Karl, Brandes Alba A., Marosi Christine, Bogdahn Ulrich, Curschmann Jürgen, Janzer Robert C., Ludwin Samuel K., Gorlia Thierry, Allgeier Anouk, Lacombe Denis, Cairncross J. Gregory, Eisenhauer Elizabeth, Mirimanoff René O., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, 10.1056/nejmoa043330
  8. Lim Stephen, Shahinian Hrayr, Maya Menahem M, Yong William, Heaney Anthony P, Temozolomide: a novel treatment for pituitary carcinoma, 10.1016/s1470-2045(06)70728-8
  9. Fadul Camilo E., Kominsky Andrew L., Meyer Louise P., Kingman Linda S., Kinlaw William B., Rhodes C. Harker, Eskey Clifford J., Simmons Nathan E., Long-term response of pituitary carcinoma to temozolomide : Report of two cases, 10.3171/jns.2006.105.4.621
  10. Syro Luis V., Uribe Humberto, Penagos Luis C., Ortiz Leon D., Fadul Camilo E., Horvath Eva, Kovacs Kalman, Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm, 10.1111/j.1365-2265.2006.02653.x
  11. Hirohata Toshio, Asano Kenichiro, Ogawa Yoshikazu, Takano Shingo, Amano Kosaku, Isozaki Osamu, Iwai Yoshiyasu, Sakata Kiyohiko, Fukuhara Noriaki, Nishioka Hiroshi, Yamada Shozo, Fujio Shingo, Arita Kazunori, Takano Koji, Tominaga Atsushi, Hizuka Naomi, Ikeda Hidetoshi, Osamura R. Yoshiyuki, Tahara Shigeyuki, Ishii Yudo, Kawamata Takakazu, Shimatsu Akira, Teramoto Akira, Matsuno Akira, DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors, 10.1210/jc.2012-2924
  12. Zacharia Brad E., Gulati Anthony P., Bruce Jeffrey N., Carminucci Arthur S., Wardlaw Sharon L., Siegelin Markus, Remotti Helen, Lignelli Angela, Fine Robert L., High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM) : A Case Series, 10.1227/neu.0000000000000251
  13. Bengtsson Daniel, Schrøder Henrik Daa, Andersen Marianne, Maiter Dominique, Berinder Katarina, Feldt Rasmussen Ulla, Rasmussen Åse Krogh, Johannsson Gudmundur, Hoybye Charlotte, van der Lely Aart Jan, Petersson Maria, Ragnarsson Oskar, Burman Pia, Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide, 10.1210/jc.2014-4350
  14. Zhong, Turkish Neurosurgery, 24, 963 (2014)
  15. Kamiya-Matsuoka Carlos, Cachia David, Waguespack Steven G., Crane Christopher H., Mahajan Anita, Brown Paul D., Nam Joo Yeon, McCutcheon Ian E., Penas-Prado Marta, Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma, 10.1007/s11102-016-0721-6
  16. Misir Krpan Ana, Dusek Tina, Rakusic Zoran, Solak Mirsala, Kraljevic Ivana, Bisof Vesna, Ozretic David, Kastelan Darko, A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma, 10.1155/2017/2419590
  17. Raverot Gérald, Sturm Nathalie, de Fraipont Florence, Muller Marie, Salenave Sylvie, Caron Philippe, Chabre Olivier, Chanson Philippe, Cortet-Rudelli Christine, Assaker Richard, Dufour Henry, Gaillard Stephan, François Patrick, Jouanneau Emmanuel, Passagia Jean-Guy, Bernier Michèle, Cornélius Aurélie, Figarella-Branger Dominique, Trouillas Jacqueline, Borson-Chazot Françoise, Brue Thierry, Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience, 10.1210/jc.2010-0644
  18. Bush Zachary M., Longtine Janina A., Cunningham Tracy, Schiff David, Jane John A., Vance Mary Lee, Thorner Michael O., Laws Edward R., Lopes M. Beatriz S., Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression, 10.1210/jc.2010-0441
  19. Salehi Fateme, Scheithauer Bernd W., Kovacs Kalman, Horvath Eva, Syro Luis V., Sharma Soniya, Manoranjan Branavan, Cusimano Michael, O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas : , 10.1227/neu.0b013e318230ac63
  20. McCormack Ann I., Wass John A. H., Grossman Ashley B., Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status : AGGRESSIVE PITUITARY TUMOURS, 10.1111/j.1365-2362.2011.02520.x
  21. Hegi Monika E., Diserens Annie-Claire, Gorlia Thierry, Hamou Marie-France, de Tribolet Nicolas, Weller Michael, Kros Johan M., Hainfellner Johannes A., Mason Warren, Mariani Luigi, Bromberg Jacoline E.C., Hau Peter, Mirimanoff René O., Cairncross J. Gregory, Janzer Robert C., Stupp Roger, MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma, 10.1056/nejmoa043331
  22. Walter T, van Brakel B, Vercherat C, Hervieu V, Forestier J, Chayvialle J-A, Molin Y, Lombard-Bohas C, Joly M-O, Scoazec J-Y, O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents, 10.1038/bjc.2014.660
  23. Raverot Gerald, Burman Pia, McCormack Ann, Heaney Anthony, Petersenn Stephan, Popovic Vera, Trouillas Jacqueline, Dekkers Olaf M, , European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas, 10.1530/eje-17-0796
  24. Murakami Mineko, Mizutani Akiko, Asano Shuichiro, Katakami Hideki, Ozawa Yoshinori, Yamazaki Kazuto, Ishida Yasuo, Takano Koji, Okinaga Hiroko, Matsuno Akira, A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report, 10.1227/neu.0b013e318217161a
  25. Kil W. J., Cerna D., Burgan W. E., Beam K., Carter D., Steeg P. S., Tofilon P. J., Camphausen K., In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide, 10.1158/1078-0432.ccr-07-1856
  26. Carlson Brett L., Grogan Patrick T., Mladek Ann C., Schroeder Mark A., Kitange Gaspar J., Decker Paul A., Giannini Caterina, Wu Wenting, Ballman Karla A., James C. David, Sarkaria Jann N., Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts, 10.1016/j.ijrobp.2009.04.026
  27. Touma Waseem, Hoostal Spencer, Peterson Richard A., Wiernik Andres, SantaCruz Karen S., Lou Emil, Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection, 10.1016/j.jocn.2017.02.052
  28. Ekeblad S., Sundin A., Janson E. T., Welin S., Granberg D., Kindmark H., Dunder K., Kozlovacki G., Orlefors H., Sigurd M., Oberg K., Eriksson B., Skogseid B., Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors, 10.1158/1078-0432.ccr-06-2053
  29. Gilbert Mark R., Wang Meihua, Aldape Kenneth D., Stupp Roger, Hegi Monika E., Jaeckle Kurt A., Armstrong Terri S., Wefel Jeffrey S., Won Minhee, Blumenthal Deborah T., Mahajan Anita, Schultz Christopher J., Erridge Sara, Baumert Brigitta, Hopkins Kristen I., Tzuk-Shina Tzahala, Brown Paul D., Chakravarti Arnab, Curran Walter J., Mehta Minesh P., Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial, 10.1200/jco.2013.49.6968
  30. Baldari S., Ferraù F., Alafaci C., Herberg A., Granata F., Militano V., Salpietro F. M., Trimarchi F., Cannavò S., First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment, 10.1007/s11102-011-0373-5
  31. Priola Stefano M., Esposito Felice, Cannavò Salvatore, Conti Alfredo, Abbritti Rosaria V., Barresi Valeria, Baldari Sergio, Ferraù Francesco, Germanò Antonino, Tomasello Francesco, Angileri Filippo F., Aggressive Pituitary Adenomas: The Dark Side of the Moon, 10.1016/j.wneu.2016.09.092
  32. Komor Jan, Reubi Jean Claude, Christ Emanuel R., Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma, 10.1007/s11102-013-0494-0
  33. Maclean Jillian, Aldridge Matthew, Bomanji Jamshed, Short Susan, Fersht Naomi, Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation, 10.1007/s11102-013-0540-y
  34. Waligórska-Stachura Joanna, Gut Paweł, Sawicka-Gutaj Nadia, Liebert Włodzimierz, Gryczyńska Maria, Baszko-Błaszyk Daria, Blanco-Gangoo Al Ricardo, Ruchała Marek, Growth hormone–secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report, 10.3171/2015.6.jns15363
  35. DeLellis RA Lloyd RV Heitz PU Eng C . Pathology and genetics of tumours of endocrine organs. In World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.
  36. Molitch Mark E., Diagnosis and Treatment of Pituitary Adenomas : A Review, 10.1001/jama.2016.19699
  37. Baldeweg SE, Pollock JR, Powell M, Ahlquist J, A spectrum of behaviour in silent corticotroph pituitary adenomas, 10.1080/02688690500081230
  38. Jouanneau Emmanuel, Wierinckx Anne, Ducray François, Favrel Véronique, Borson-Chazot Françoise, Honnorat Jérôme, Trouillas Jacqueline, Raverot Gérald, New targeted therapies in pituitary carcinoma resistant to temozolomide, 10.1007/s11102-011-0341-0
  39. Hagen C, Schroeder H D, Hansen S, Hagen C, Andersen M, Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy, 10.1530/eje-09-0389
  40. Brown R. L, A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry, 10.1530/eje.1.02141
  41. Lania Andrea G., Ferrero Stefano, Pivonello Rosario, Mantovani Giovanna, Peverelli Erika, Di Sarno Antonella, Beck-Peccoz Paolo, Spada Anna, Colao Annamaria, Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation, 10.1210/jc.2009-1360
  42. Saeger W., Ludecke D. K, Buchfelder M., Fahlbusch R., Quabbe H.-J., Petersenn S., Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry, 10.1530/eje.1.02326
  43. Di Ieva Antonio, Rotondo Fabio, Syro Luis V., Cusimano Michael D., Kovacs Kalman, Aggressive pituitary adenomas—diagnosis and emerging treatments, 10.1038/nrendo.2014.64
  44. Lopes M. Beatriz S., The 2017 World Health Organization classification of tumors of the pituitary gland: a summary, 10.1007/s00401-017-1769-8
  45. Trouillas Jacqueline, , Roy Pascal, Sturm Nathalie, Dantony Emmanuelle, Cortet-Rudelli Christine, Viennet Gabriel, Bonneville Jean-François, Assaker Richard, Auger Carole, Brue Thierry, Cornelius Aurélie, Dufour Henry, Jouanneau Emmanuel, François Patrick, Galland Françoise, Mougel François, Chapuis François, Villeneuve Laurent, Maurage Claude-Alain, Figarella-Branger Dominique, Raverot Gérald, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up, 10.1007/s00401-013-1084-y
  46. Raverot Gérald, Dantony Emmanuelle, Beauvy Julie, Vasiljevic Alexandre, Mikolasek Sara, Borson-Chazot Françoise, Jouanneau Emmanuel, Roy Pascal, Trouillas Jacqueline, Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification, 10.1210/jc.2017-00773
Bibliographic reference McCormack, Ann ; Dekkers, Olaf M ; Petersenn, Stephan ; Popovic, Vera ; Trouillas, Jacqueline ; et. al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.. In: European journal of endocrinology, Vol. 178, no.3, p. 265-276 (2018)
Permanent URL http://hdl.handle.net/2078.1/201710